(+)-Griffipavixanthone (GPX), a dimeric xanthone natural product, was isolated in 1982 and was reported to possess anticancer activity by downregulating the Raf/Ras pathway which accounts for approximately one third of human cancers. Upon successful racemic and asymmetric syntheses of GPX by the Porco laboratory, experimentation concerning the intracellular target(s) has been explored as part of an ongoing collaboration with the National Cancer Institute (NCI). Our studies have focused on optimization of the final deprotection step and evaluation of late-stage oxidation chemistry. Through these efforts, a focused library of novel GPX analogues has been synthesized and subjected to biological evaluation to construct a working structure-activity relationship (SAR) hypothesis for the GPX dimeric scaffold.

Synthesis of novel griffipavixanthone analogues as anticancer agents

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.